报告题目：Automation + Miniaturization = Acceleration
报告时间：2026年1月16日（星期五）上午10:00—12:00
报告地点：五山校区逸夫工程馆105会议室
报 告 人：Alexander Dömling（帕拉茨基大学 教授）
主办单位：化学与化工学院
报告人简介：
Prof Alexander Dömling (ERA Chair of Innovative Chemistry Group at the Palacky University Olomouc) . He devotes his academic life to the design and discovery of bioactive compounds for difficult targets such as protein protein interactions, transcription factors, or RNA. He studied multi-component reactions with Ivar Ugi at the Technical University Munich (PhD), and with double Nobel laureate Barry Sharpless at The Scripps Research Institute (PD). At the University of Pittsburgh, he became associate and full professor and he introduced the “google-like” web-based technology ANCHOR.QUERY together with Carlos Camacho. ANCHOR.QUERY can screen very large (billions) of virtual compounds in just seconds for pharmacophores and based on key interacting fragments, e.g. large amino acid side chains of amino acids (in PPIs). Interestingly the resulting virtual hits can be instantaneously synthesized using convergent and fast multicomponent reaction chemistry in order to test the virtually generated hypothesis. From 2011 till 2022 he was Professor and chair of Drug Design at the University of Groningen. Another development is the technology platform Automated, miniaturized and accelerated drug discovery (AMADEUS) which was recently rewarded by an ERC Advanced grant. Here a fundamentally novel approach towards preclinical drug discovery and development is introduced by blending Instant Chemistry, nL dispensing, HT purification, HTS and machine learning. The indication areas Alexander Dömling is interested in are cancer immunology, infectious diseases and metabolic disorders. He has published more than 300 scientific articles, reviews and applied for >70 patents. Additionally, Alexander Dömling is a serial entrepreneur trying to make the expression “from bench to bedside” become true.
报告摘要：
In my talk I will give an overview of my recent work in organic and medicinal chemistry. My work largely focuses on isocyanide-based multicomponent reaction chemistry (IMCR). In numerous publications I have shown the design of novel scaffolds and applications of IMCR in medicinal chemistry. I am convinced, the face of organic and medicinal chemistry will dramatically change in the next future involving robotics, automation and AI driven syntheses and property optimizations. The mantra ‘Automation + Miniaturization = Acceleration’ is successfully applied in many research areas and technologies, but not in synthetic chemistry, which is largely believed to be not automatable. However, with the potential to accelerate discoveries while flattening costs, increase safety, streamline data generation, enhance reproducibility, and lower the environmental footprint, automation and miniaturization are two promising approaches to synthesis and are worthwhile to invest in. I will introduce the concept of AMADEUS (Automated, MiniAturizeD, and acceleratEd drUg diScovery), a technology platform, which is able to synthesize in a fully autonomous manner thousands of small molecules per day in nano- or picolitre volumes, based on hundreds of chemistries, efficiently screened and optimized for properties using artificial intelligence.